In this episode of Data in Biotech, host Ross Katz sits down with Scott Lipnick, Co-Founder and President of Etiome, to explore how preemptive medicine is changing the way biotech approaches therapeutic modeling and intervention. 

Discover how Etiome’s recently launched, AI-driven platform is built to detect disease earlier, identify precise biomarkers, and create stage-specific treatments—all before symptoms arise. 

It’s a visionary approach to healthcare focused on preserving health, not just managing illness.

What You'll Learn in This Episode:

• Why Scott Lipnick believes the future of medicine lies in preemptive care.
• How Etiome uses AI to map disease progression at the cellular level.
• The role of biomarkers in identifying disease before symptoms surface.
• How Etiome applies its Temporal Biodynamics platform across diseases.
• What venture creation looks like at Flagship Pioneering.

Meet Our Guest

Scott Lipnick is the Co-founder and President of Etiome. At the forefront of preemptive medicine, Scott’s work focuses on predicting disease progression and delivering personalized, early-stage interventions using cutting-edge AI and molecular tools.

About The Host

Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation.

Connect with Our Guest:

• Sponsor: CorrDyn, a data consultancy
• Find out more about Etiome
• Connect with Scott on LinkedIn

Connect with Us:

• Follow the podcast for more insightful discussions on the latest in biotech and data science.
• Subscribe and leave a review if you enjoyed this episode!

Sponsored by…

This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.